Amgen dealt blow as FDA rules 'patent dance' optional

The US Food and Drug Administration (FDA) has denied Amgen’s petition asking that the so-called patent dance between a biosimilar maker and the product’s innovator be a mandatory requirement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Apotex ordered to provide 180 days’ biosimilar notice to Amgen

15 December 2015 Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

Americas

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More on this story

Americas

Apotex ordered to provide 180 days’ biosimilar notice to Amgen

15 December 2015 Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

Americas

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More on this story

Americas

Apotex ordered to provide 180 days’ biosimilar notice to Amgen

15 December 2015 Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.

Americas

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

Americas

Amgen antibody patents ‘too broad’, says Fed Circuit

16 February 2021 The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Amgen dealt blow as FDA rules 'patent dance' optional

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features